PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial | Zendy

Daniela Fiore | Zendy; Daniele Gianfrilli | Zendy; Elisa Giannetta | Zendy; Nicola Galea | Zendy; Giuseppe Panio | Zendy; Carla Di Dato | Zendy; Riccardo Pofi | Zendy; Carlotta Pozza | Zendy; Emilia Sbardella | Zendy; Iacopo Carbone | Zendy; Fabio Naro | Zendy; Andrea Lenzi | Zendy; Mary Anna Venneri | Zendy; Andrea M. Isidori | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial

Author(s) -

Daniela Fiore,

Daniele Gianfrilli,

Elisa Giannetta,

Nicola Galea,

Giuseppe Panio,

Carla Di Dato,

Riccardo Pofi,

Carlotta Pozza,

Emilia Sbardella,

Iacopo Carbone,

Fabio Naro,

Andrea Lenzi,

Mary Anna Venneri,

Andrea M. Isidori

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-4252

Subject(s) - adipose tissue , sildenafil , medicine , endocrinology , type 2 diabetes , placebo , diabetes mellitus , waist , body mass index , pathology , alternative medicine

Visceral adiposity plays a significant role in cardiovascular risk. PDE5 inhibitors (PDE5i) can improve cardiac function and insulin sensitivity in type 2 diabetes patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research